Managing bevacizumab-induced intraocular inflammation

• Published in: Indian journal of ophthalmology 2012-07, Vol.60 (4), p.311-313
• Main Authors: Sinha, Subijay, Vashisht, Nagender, Venkatesh, Pradeep, Garg, Sat Pal
• Format: Article
• Language: English
• Subjects: Adult; Amaurosis; amaurosis hemianopia; Angiogenesis Inhibitors - administration & dosage; Antibiotics; Antibodies, Monoclonal, Humanized - administration & dosage; Antivascular endothelial growth factor; Apoptosis; Asian Indian; BARC I-125 Ocu-Prosta seeds; Bevacizumab; Branch retinal vein occlusion; Brief Communications; capsulolenticular cataract; Care and treatment; Cataract; choroidal melanoma; conjunctiva; Cross-cylinder technique; Diabetic retinopathy; Diagnosis; Endophthalmitis; Endophthalmitis - diagnosis; Endophthalmitis - drug therapy; eye lid; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; glaucoma; Humans; inflammation; Interpretation; intraocular pressure; Intraoperative application of mitomycin C; intravitreal bevacizumab; Intravitreal Injections; laser; lenticular cataract; leukoma; Lucentis; macular edema; magnetic resonance imaging; Microbial etiology; Microscopy, Acoustic; mitomycin C; mucopurulent keratitis; mydriasis; ocular inflammation; ophthalmia chronica; ophthalmic purulentis; Ophthalmology; Ophthalmoscopy; orbit; photoastigmatic refractive keratectomy; plaque brachytherapy; postoperative complications; preoperative subconjunctival injection; prevention and control; recurrence rate; recurrent pterygium; refractive surgery; retinal ganglion cells; retinal ischemia; Retinal Pigment Epithelium - pathology; retinoblastoma; Risk factors; suppurative keratitis; surgery; Time Factors; Tomography, Optical Coherence; tumor necrosis factor-alpha; Vascular Endothelial Growth Factor A - antagonists & inhibitors; vasoproliferative tumors
• ISSN: 0301-4738; 1998-3689
• DOI: 10.4103/0301-4738.98712

The outcome of four cases of sterile endophthalmitis that developed after intravitreal injections of bevacizumab has been reported here. All four eyes received 1.25 mg/0.05 ml intravitreal bevacizumab from 0.2-ml aliquots for different etiologies. The inflammation predominantly involved the anterior chamber with mild vitreous reaction. All patients were culture negative and regained preinjection visual acuity and were culture negative following intravitreal antibiotic administration. This report highlights that intravitreal bevacizumab can cause sterile endophthalmitis and this has to be kept in mind, and clinical judgment should be used to differentiate it from infective endophthalmitis.